Drugs & Aging

, Volume 23, Issue 1, pp 71–81 | Cite as

The Effect of Direct-to-Consumer Advertising on Prescription Drug Use by Older Adults

Original Research Article

Abstract

Background and objective

Although older adults are frequent consumers of prescription drugs and increasingly the intended audience of direct-to-consumer advertising (DTCA) marketing efforts, little is known about the effect of DTCA on older adults’ prescription drug-seeking behaviour. In response, the objective of this study is to examine factors associated with requesting a prescription drug from a physician following exposure to DTCA among older adults, and whether the drug or other medical treatment was prescribed during the encounter.

Methods

A secondary data analysis of the “Public Health Impact of Direct-to-Consumer Advertising of Prescription Drugs”, a data set publicly available through the Inter-university Consortium for Political and Social Research (ICPSR 3687), was conducted. For the purposes of this study, only those respondents who indicated that they had been exposed to DTCA (n = 2601) were included in the study sample. Using a two-step weighted logistic regression approach, separate models were estimated to examine first, whether a request for the advertised drug was made following exposure to DTCA and secondly, the outcomes of any patient-physician encounters that occurred following exposure to DTCA.

Results

Descriptive analysis of the outcome variables revealed that, among respondents exposed to DTCA, 31% (n = 801) requested a prescription drug from their physician. Approximately 5% of those who made a request were ≥75 years of age. Among respondents requesting a prescription drug, 69% (n = 556) received a prescription in response to their request, of whom, approximately 5% were ≥75 years of age. Multivariate findings suggest that although adults ≥75 years of age are less likely to request a prescription drug following exposure to DTCA (odds ratio [OR] = 0.58; p = 0.032), when they do approach their physicians, they are more likely to receive recommendations for further treatment, with ORs indicating a 250% (OR = 3.507; p = 0.002) increase in the odds of further referral among adults ≥75 years of age.

Conclusion

Overall, results from the study suggest that DTCA influences the patient-doctor relationship and prescription drug acquisition behaviour of patients; however, the nature of the effect of DTCA on older adults is complex. Because future cohorts of older adults may be more comfortable about requesting prescription drugs and the consumer-driven approach to obtaining medical care, understanding the impact of DTCA on older consumers represents an important area for further inquiry.

Keywords

Prescription Drug Terbinafine Prescription Drug Coverage Weighted Logistic Regression Frequent Consumer 

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The author has no conflicts of interest that are directly relevant to the content of this study.

The authors are grateful for public access to the study data through the Inter-university Consortium for Political and Social Research and for the helpful comments provided by the three anonymous rewiewers. The views presented here belong to the authors, who alone are responsible for any errors or omissions, and who accept all responsibility for the presentation and content. An earlier version of this paper was presented at the 57th Annual Scientific Meeting of the Gerontological Society of America, November 2004, Washington, DC.

References

  1. 1.
    Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346(7): 498–505PubMedCrossRefGoogle Scholar
  2. 2.
    Heffler S, Levit K, Smith S, et al. Health spending growth up in 1999: faster growth expected in the future. Health Aff (Millwood) 2001; 20(2): 193–203CrossRefGoogle Scholar
  3. 3.
    IMS Health. Integrated promotional services TM and CMR, 6/2004 [online]. Available from URL: http://www.im-shealth.com/ims/portal/front/articleC/0,2777,6599_44304752_44889690,00.html [Accessed 2005 Sep 15]Google Scholar
  4. 4.
    Robinson AR, Hohmann KB, Rifkin JI, et al. Direct to consumer pharmaceutical advertising: physician and public opinion and potential effects on the physician patient relationship. Arch Intern Med 2004; 164: 427–32PubMedCrossRefGoogle Scholar
  5. 5.
    Lipsky MS, Taylor CA. The opinions and experiences of family physicians regarding direct to consumer advertising. J Fam Pract 1997; 45(6): 495–9PubMedGoogle Scholar
  6. 6.
    Weissman JS, Blumenthal D, Silk AJ, et al. Physician’s report on patient encounters involving direct to consumer advertising. Health Aff (Millwood) 2004; Suppl Web Exclusives (Jan–Jun): W4219–33Google Scholar
  7. 7.
    Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests for direct-to-consumer advertised an-tidepressants: a randomized controlled trial. JAMA 2005; 293(16): 1995–2002PubMedCrossRefGoogle Scholar
  8. 8.
    Weissman JS, Blumenthal D, Silk AJ, et al. Consumers’ report on the health effects of direct to consumer drug advertising. Health Aff (Millwood) 2003; Suppl Web Exclusives (Jan–Jun): W382–95Google Scholar
  9. 9.
    Aikin KJ, Swasy JL, Braman AC. Patient and physician attitudes and behaviors associated with DTC promotion of prescription drugs: summary of FDA survey research results. Rockville (MD). Centre for Drug Evaluation and Research, FDA. US Dept of Health and Human Services; 2004 Nov 19Google Scholar
  10. 10.
    Slaughter E, Schumacher M. Prevention’s international survey on Wellness and consumer reactions to DTCA of Rx drugs. Emmaus (PA): Prevention Magazine, Kodak Inc., 2000/2001Google Scholar
  11. 11.
    Kaiser Family Foundation. Understanding the effects of direct-to-consumer prescription drug advertising. Menlo Park (CA): The Henry J. Kaiser Family Foundation, 2001Google Scholar
  12. 12.
    Murray E, Lo B, Pollack L, et al. Direct to consumer advertising: public perceptions of its effects on health behaviors: healthcare and the doctor patient relationship. J Am Board Fam Pract 2004; 17(1): 6–18PubMedCrossRefGoogle Scholar
  13. 13.
    Doucette WR, Schommer JC. Consumer preferences for drug information after direct to consumer advertising. Drug Inf J 1998; 32: 1081–8Google Scholar
  14. 14.
    Salom IL, Davis K. Prescribing for older patients: how to avoid toxic drug reactions. Geriatrics 1995; 50(10): 37–43PubMedGoogle Scholar
  15. 15.
    Beijer HJM, de Blaey CJ. Hospitalizations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002; 24(2): 46–54PubMedCrossRefGoogle Scholar
  16. 16.
    Spencer MM, Teleki SR, Cheetham TC, et al. Direct-to-con-sumer advertising of cox-2 inhibitors: effect on appropriateness of prescribing. Med Care Res Rev 2005; 62(5): 544–59CrossRefGoogle Scholar
  17. 17.
    Corney RH. Sex differences in general practice attendance and help seeking for minor illness. J Psychosom Res 1990; 34(5): 525–34PubMedCrossRefGoogle Scholar
  18. 18.
    Gibjsers van Wijk CM, van Vliet KP, Kolk AM. Gender perspectives and quality of care: towards appropriate and adequate health care for women. Soc Sci Med 1996; 43(5): 707–20CrossRefGoogle Scholar
  19. 19.
    Shi L. Sociodemographic characteristics and individual health behaviors. South Med J 1998; 91(10): 933–41PubMedCrossRefGoogle Scholar
  20. 20.
    Briesacher B, Limcangco R, Gaskin D. Racial and ethnic disparities in prescription coverage and medication use. Health Care Financ Rev 2003; 25(2): 63–76PubMedGoogle Scholar
  21. 21.
    Ayanian JZ, Weissman JS, Schneider EC, et al. Unmet health needs of uninsured adults in the United States. JAMA 2000; 284: 2061–9PubMedCrossRefGoogle Scholar
  22. 22.
    Gonul FF, Carter F, Wind J. What kind of patients and physicians value direct-to-consumer advertising of prescription drugs. Health Care Manag Sci 2000; 3(3): 215–26PubMedCrossRefGoogle Scholar
  23. 23.
    Allison PD. Event history analysis: regression for longitudinal event data. Beverly Hills (CA): Sage, 1984Google Scholar
  24. 24.
    StataCorp. Statistical Software: release 9.0. College Station (TX): StataCorp., 2005Google Scholar
  25. 25.
    Woloshin S, Schwartz LM, Tremmel J, et al. Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet 2001; 358(9288): 1141–6PubMedCrossRefGoogle Scholar
  26. 26.
    Hwang W, Weller W, Ireys H, et al. Out-of-pocket medical spending for care of chronic conditions. Health Aff (Millwood) 2001; 20(6): 267–78CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Department of Comm. Med.West Virginia University School of MedicineMorgan-townUSA

Personalised recommendations